Updates on immunotherapy toxicity : understand, explore and improve itoxicities management/ Stephane Champiat Medical Oncologist @champiatMD @gustaveroussy
Joined September 2016
- Tweets332
- Following40
- Followers656
- Likes11
immunotox report retweeted
C'est parti pour la 5ème édition du symposium ITOX sur les #toxicités des #immunothérapies dans le #cancer
#ITOX22
▶️enseignement.gustaveroussy.f…
immunotox report retweeted
Symposium iTOX 2022 à la @ciup_fr ! Identifier et comprendre les toxicités des immunothérapies anti tumorales @GustaveRoussy #immunotherapy #toxicities #irAE #CancerImmunotherapy
immunotox report retweeted
An important conversation to take part in, the goal is to:
1. Identify the clinical issues for management of patients receiving IO in the context of covid19
2. Identify the important clinical and translational research questions, and how to tackle them – at Baltimore, MD
COVID-19 Implications for I-O Patient Management @sitcancer sitcancer.org/communities/co…
immunotox report retweeted
Four years’ experience of @GustaveRoussy in handling immune-related adverse events of ICB. Interestingly, initiation of #immunotherapy in patients with autoimmune comorbidity was assessed as feasible in 93% of cases
sciencedirect.com/science/ar…
immunotox report retweeted
🎥 Pourquoi l'#immunothérapie peut-elle provoquer des effets secondaires ? Quels sont les plus fréquents ? Comment les gérer ?
Les explications en vidéo du Dr Aurélien Marabelle @GustaveRoussy et du Pr Olivier Lambotte, spécialistes en immunothérapie : ▶️youtu.be/Zn82V9X54bI
immunotox report retweeted
[Symposium]
4th edition of ITOX on Cancer Immunotherapy Adverse Events
gathering Clinicians, Scientists and Pharmacists to share experiences about toxicities
May 14, 2020 from 2 PM to May 15,2020 5 PM - Paris
Online registration until May 04, 2020
⏩ formation.gustaveroussy.fr/s…
immunotox report retweeted
[symposium]
4ème édition iTOX 2020 sur toxicités des immunothérapies anticancéreuses - 14 et 15 mai - Paris 15e
à destination des médecins, pharmaciens et chercheurs
inscriptions : formation.gustaveroussy.fr/s…
immunotox report retweeted
It is AMAZING how much information we can learn in each iTOX Committee!! Every time I feel l am still on my first-year of residency 🤓📝 learning 📈exponentially on #immunoOncology and toxicity @iTOXreport @GustaveRoussy – at Villejuif, France
immunotox report retweeted
Nice talk by Julie Belliere @CHUdeToulouse at @IUCTOncopoleICR on immunosuppressive drugs for irAE. Other IS than TNFa inhibitors should be considered in cortico-resistant irAE especially IL6 inh. @iTOXreport
immunotox report retweeted
Comprendre le fonctionnement du système immunitaire et des immunothérapies: c’est l’objectif de notre livre #Immunothérapies avec Nicolas Noël
Disponible dans toutes les bonnes librairies ;)
editions-tredaniel.com/immun…
immunotox report retweeted
Can pts who develop immune-related adverse events (AEs) on PD-1 or PD-L1 inhibitor immunotherapy be re-challenged later? Cohort of 93 pts from @GustaveRoussy tested, w 55% developing AEs w 2nd administration, typically less severe than 1st exposure ja.ma/2IooajP
immunotox report retweeted
Aujourd'hui @GustaveRoussy, se tient la 3ème édition du symposium iTOx pour tout savoir sur les toxicités des #immunothérapies anticancéreuses | #cancer #oncologie
immunotox report retweeted
A man in his 40s given pembrolizumab for malignant melanoma developed diffuse darkening of his skin, nail beds, and sclera after starting treatment; the image shows him holding a recent driver’s license photo. What is the cause of the change? jamanetwork.com/journals/jam…
immunotox report retweeted
Hypeprogressive disease #HPD in a a Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE) @EUplatinum europeanurology.com/article/…
immunotox report retweeted
Studies of cancer drugs often use terms that downplay the seriousness of adverse events: @oncology_bg et al call for greater clarity and transparency bmj.com/content/363/bmj.k438…
immunotox report retweeted
Hyperprogressive disease #HPD : recognizing a novel pattern to improve patient management @NatRevClinOncol @charles_ferte @drcmassard @jsoriamd @BenjaminBesseMD @RobertoFerrara_ @GustaveRoussy nature.com/articles/s41571-0…
immunotox report retweeted
Neurological Complications Associated W Anti-Programmed Death 1 (PD-1) Therapies: neuropathies, headache, more ja.ma/2vL8mEo
immunotox report retweeted
Multicentric (n=5) validation of our initial findings #ESMO16. HPD is frequent and deleterious. teapawt.net/tony_calles/status/903…
Hypperprogressive disease to #immunotherapy takes form in lung cancer patients: 16% in single institution experience (n=242) #ESMO17 #LCSM
immunotox report retweeted
Il y'a 10 jours, vous étiez plus de 160 à y assister…
Le replay📽️ du #Symposium #iTOX est disponible gratuitement ! formation.gustaveroussy.fr/s…
